Victory Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Victory Capital Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-238	Closed	-$1.93K	–	2633
2023 Q1	$1.93K	Sell	238 -3	-1%	-$40	﹤0.01%	2585
2022 Q4	$2.85K	Hold	241	–	–	﹤0.01%	2577
2022 Q3	$3K	Sell	241 -50	-17%	-$1.29K	﹤0.01%	2691
2022 Q2	$10K	Sell	291 -1	-0.3%	-$31	﹤0.01%	2654
2022 Q1	$8K	Sell	292 -8	-3%	-$343	﹤0.01%	2692
2021 Q4	$13K	Sell	300 -9	-3%	-$561	﹤0.01%	2720
2021 Q3	$21K	Sell	309 -16	-5%	-$1.17K	﹤0.01%	2728
2021 Q2	$25K	Buy	325 +23	+8%	+$1.4K	﹤0.01%	2694
2021 Q1	$20K	Buy	302 +87	+40%	+$6.78K	﹤0.01%	2717
2020 Q4	$7K	Buy	215 +19	+10%	+$845	﹤0.01%	2524
2020 Q3	$11K	Buy	196 +28	+17%	+$1.66K	﹤0.01%	2458
2020 Q2	$6K	Sell	168 -177	-51%	-$6.05K	﹤0.01%	2486
2020 Q1	$8K	Buy	+345	New	+$14.6K	﹤0.01%	3394
2019 Q4	–	Sell	-143	Closed	-$7K	–	3426
2019 Q3	$7K	Buy	+143	New	+$10.3K	﹤0.01%	3376

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Victory Capital Management's DMK Position: Q2 2023 in Review

Victory Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 238 shares — an estimated $1.93K sold.

Victory Capital Management first reported a position in DMK in Q3 2019 and held it in 14 quarters. The position peaked at $25K in Q2 2021. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Victory Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Victory Capital Management sold 238 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $1.93K.
Victory Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2019 and held it in 14 quarters.
Victory Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $25K in Q2 2021.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.